查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870750

急性肺損傷治療市場按藥物類別、給藥途徑、最終用戶、通路、患者年齡層和治療環境分類－2025-2032年全球預測

Acute Lung Injury Treatment Market by Drug Class, Administration Route, End User, Distribution Channel, Patient Age Group, Treatment Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性肺損傷治療市場將成長至 45.2 億美元，複合年成長率為 4.31%。

關鍵市場統計數據
基準年 2024 32.2億美元
預計年份：2025年 33.6億美元
預測年份 2032 45.2億美元
複合年成長率 (%) 4.31%

本文全面概述了急性肺損傷的臨床挑戰和治療重點，為相關人員提供指南，以製定循證治療和交付路徑。

急性肺損傷仍然是加護治療和危重症監護領域的核心臨床挑戰，促使人們致力於改進治療方法、最佳化診療路徑，並將不斷更新的實證醫學證據融入臨床實踐。本導論透過綜合闡述當前臨床要務，為減少人工呼吸器相關性損傷、控制發炎、增強肺泡功能以及預防常伴隨嚴重呼吸功能障礙發生的器官衰竭級聯反應奠定了基礎。它將治療藥物類別、給藥途徑、醫療環境和分銷框架置於一個切實可行的決策框架中，旨在為臨床醫生、醫院管理者、支付方和生命科學經營團隊提供直接的參考。

臨床進展、不斷發展的醫療服務模式和現代分銷方式的融合如何重塑急性肺損傷治療的發展和醫院的應用

急性肺損傷的治療格局正經歷著一場變革性的轉變，這主要得益於藥物研發的進步、臨床指南的不斷完善以及高風險重症醫療機構護理模式的改變。對發炎路徑和肺泡修復機制的新認知正在重塑現有藥物的理論基礎，促使人們重新思考皮質類固醇的給藥策略，並日益關注輔助性肺功能調節。同時，通氣策略和鎮靜通訊協定的改進正在影響床邊藥物介入的實施，並為那些與現代呼吸照護通訊協定具有協同作用的治療方法方法創造了機會。

評估關稅引發的供應鏈壓力如何推動急性肺損傷治療的多元化、近岸外包和供應連續性策略

關稅的實施使得人們更加關注用於急性肺損傷治療的藥品原料和成品的供應鏈設計、製造地選擇和籌資策略。傳統上依賴地理位置集中化生產的公司正在重新評估供應商多元化策略，以降低關稅風險和清關複雜性。對許多相關人員，這促使他們重新重視近岸外包方案、原料藥（API）的雙重籌資策略以及能夠預見跨國成本波動的合約條款。

按藥物類別、給藥途徑、臨床環境和通路進行詳細的細分分析，將臨床應用與營運執行聯繫起來。

細分市場分析揭示了不同藥物類別、給藥途徑、終端用戶畫像、分銷管道、患者人口統計特徵和治療環境之間存在不同的需求促進因素和營運考慮。在所有藥物類別中，皮質類固醇類藥物因其抗發炎特性而備受關注，尤其是地塞米松、Hydrocortisone和Methylprednisolone等藥物。同時，順式阿曲庫銨、羅庫溴銨和維庫溴銨等神經肌肉阻斷劑仍是促進肺部保護性通氣的重要工具。肺表面活性物質療法，例如貝拉坦和波拉坦α等藥物，在某些臨床情況下仍然十分重要，因為調節肺泡表面張力可以帶來臨床獲益；吸入性血管擴張劑，例如一氧化氮，則被用作輔助治療，以改善難治性低氧血症患者的氧合。

對影響全球急性肺損傷治療普及的區域醫療服務模式、監管趨勢和供應鏈進行比較分析

區域趨勢將影響全球主要區域急性肺損傷加護病房的臨床實踐模式、監管參與和商業性策略。在美洲，整合的醫院網路和完善的三級醫療機構推動了對強調快速轉入重症監護室管理的通訊協定的需求，這些方案需要先進的人工呼吸器技術和完善的重症監護室藥房基礎設施的支持。這些特點有利於那些能夠與複雜的治療路徑無縫銜接，並能調動醫院處方集委員會和加護治療學會等相關人員的治療方法方案。

策略性企業專注於臨床證據、生產韌性和夥伴關係模式，以加強急性肺損傷的治療服務。

在公司層面，我們看到企業正加大對臨床開發、生產韌性和合作夥伴關係的策略性投資，以加速臨床應用並加強供應連續性。領先的藥物研發企業優先考慮證明藥物與現代呼吸器和鎮靜通訊協定相容性的證據，同時也在投資於製劑創新和包裝技術，以實現在急診環境中快速給藥。製造商與合約研發生產機構（CDMO）之間的策略聯盟日益普遍，旨在提高生產靈活性並支持地理多元化。

製造商和醫療保健領導者可採取的切實可行的策略挑戰，以增強臨床應用、供應鏈韌性和整合式護理路徑

產業領導者應優先採取一系列切實可行的措施，以提高急性肺損傷治療的臨床療效、供應穩定性和商業性效益。首先，應使臨床開發和上市後證據項目與現代加護治療實踐相契合，設計的研究應反映現代通氣策略、常見合併症以及對臨床醫生和醫院處方委員會至關重要的可操作終點。這將有助於縮小監管核准與實際效用之間的證據差距，從而加快產品推廣應用並最佳化治療路徑。

採用穩健的混合調查方法，結合證據綜合、相關人員訪談和供應鏈分析，得出具有臨床指導意義的研究結果。

本分析的調查方法結合了系統性的證據綜合、與關鍵相關利益者的直接對話以及嚴格的資料交叉檢驗，以確保其可靠性和相關性。此方法首先透過全面審查同行評審的臨床文獻、監管核准和產品資訊以及公開的臨床試驗註冊庫，為相關治療領域建立臨床證據和安全性概況的基礎。其次，對加護治療、醫院藥局主任和採購人員進行結構化訪談，以深入了解通訊協定選擇趨勢、營運限制和實施障礙等方面的實際情況。

將治療方面的進展轉化為患者療效的可衡量改善，需要整合和協調臨床、營運和供應鏈方面的要求。

總之，推進急性肺損傷治療需要在臨床證據累積、運作執行和供應鏈韌性方面取得協同進展。皮質類固醇、神經肌肉阻斷劑、界面活性劑和血管擴張劑等治療藥物在現代治療模式中各自發揮不同的作用，其有效應用取決於給藥途徑、護理環境和配送模式是否符合急性護理的實際情況。應對關稅和區域監管差異造成的供應脆弱性，需要採取更積極主動的籌資策略和社區層面的努力，以確保患者能夠持續獲得治療。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基於新興生物標記的個人化治療在急性肺損傷管理的應用
  • 採用照護現場超音波通訊協定最佳化急性肺損傷患者的液體管理
  • 間質幹細胞療法治療急性呼吸窘迫症候群的臨床試驗進展
  • 整合人工智慧驅動的預測分析技術以早期發現急性肺損傷風險
  • 針對急性肺損傷的新型吸入抗發炎藥物的快速監管核准流程
  • 引入遠端ICU平台以支援急性肺損傷患者的人工呼吸器加護病房策略
  • 開發體外二氧化碳清除系統以改善重症急性肺損傷的治療效果
  • 穿戴式生物感測器在高風險患者中廣泛用於連續呼吸監測
  • 一項真實世界證據研究評估了高流量氧氣鼻管在中度至重度急性肺損傷 (ALI) 中的療效。
  • 與製藥公司進行合作研究，重點在於用於治療肺部發炎的脂質奈米顆粒藥物遞送系統。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 急性肺損傷治療市場（依藥物類別分類）

  • 皮質類固醇
    • 地塞米松
    • Hydrocortisone
    • Methylprednisolone
  • 神經肌肉阻斷劑
    • 順式曲庫銨
    • 羅庫溴銨
    • 維庫溴銨
  • 界面活性劑
    • 維拉克坦
    • 豬糞α
  • 血管擴張劑
    • 一氧化氮

9. 依給藥途徑分類的急性肺損傷治療市場

  • 吸入
  • 靜脈注射

第10章 按最終用戶分類的急性肺損傷治療市場

  • 門診治療中心
  • 醫院
  • 研究所

第11章 急性肺損傷治療市場（依通路分類）

  • 醫院藥房
    • 住院藥房
    • 門診藥房
  • 網路藥房
    • 直接送達患者
    • 第三方履約
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章 依患者年齡層別分類的急性肺損傷治療市場

  • 成人
  • 老年人
  • 兒童

第13章 急性肺損傷治療市場：依治療場所分類

  • 急診室
  • 普通病房
  • 加護病房

第14章 急性肺損傷治療市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 急性肺損傷治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國急性肺損傷治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medtronic plc
    • Koninklijke Philips NV
    • General Electric Company
    • Dragerwerk AG & Co. KGaA
    • Fisher & Paykel Healthcare Corporation Limited
    • Hamilton Medical AG
    • Smiths Group plc
    • Getinge AB
    • Vyaire Medical, Inc.
    • Nihon Kohden Corporation
Product Code: MRR-1A1A064C0344

The Acute Lung Injury Treatment Market is projected to grow by USD 4.52 billion at a CAGR of 4.31% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.22 billion
Estimated Year [2025] USD 3.36 billion
Forecast Year [2032] USD 4.52 billion
CAGR (%) 4.31%

Comprehensive framing of acute lung injury clinical challenges and therapeutic priorities to orient stakeholders toward evidence-based treatment and delivery pathways

Acute lung injury remains a central clinical challenge across critical care and emergency medicine, prompting intensive efforts to refine therapeutic approaches, optimize care pathways, and integrate evolving evidence into practice. This introduction frames the landscape by synthesizing the prevailing clinical imperatives: reducing ventilator-associated injury, managing inflammation, enhancing alveolar function, and attenuating the cascade of organ dysfunction that often accompanies severe respiratory compromise. It situates therapeutic classes, administration routes, care settings, and distribution frameworks within a practical decision-making context that speaks directly to clinicians, hospital leaders, payers, and life sciences executives.

Transitioning from clinical priorities to system-level implications, this section underscores how multidisciplinary coordination, supply chain resilience, and regulatory clarity are shaping implementation timelines for novel and repurposed interventions. It highlights the need for integrated protocols that reconcile pharmacologic strategies with ventilatory management and supportive care, while also calling attention to the crucial role of real-world evidence and clinician preference in driving adoption. The introduction sets expectations for the remainder of the report by outlining the analytical lens applied throughout: a synthesis of clinical evidence, regulatory signals, stakeholder interviews, and distribution dynamics intended to support informed strategic choices.

How converging clinical advances, care delivery evolution, and distribution modernization are reshaping acute lung injury therapeutic development and hospital adoption

The therapeutic landscape for acute lung injury is undergoing transformative shifts driven by advances in drug development, evolving clinical guidelines, and changes in care delivery models within high-acuity environments. Novel insights into the inflammatory pathways and alveolar repair mechanisms are reshaping the rationale for existing drug classes, prompting reconsideration of corticosteroid dosing strategies and renewed interest in adjunctive agents that modulate pulmonary mechanics. Concurrently, precision in ventilation strategies and sedation protocols is influencing how pharmacologic interventions are deployed at the bedside, creating opportunities for therapies that demonstrate synergy with contemporary respiratory care protocols.

In parallel, the commercialization and distribution environment is adapting to digital enablement, inventory optimization, and heightened scrutiny of supply continuity. These forces drive greater collaboration between manufacturers, hospital pharmacies, and specialty distributors, while also elevating the importance of value demonstration and post-market evidence generation. Regulatory pathways are increasingly emphasizing robust safety monitoring and real-world performance data, which in turn informs payer and hospital procurement expectations. Together, these dynamics are producing a landscape that rewards integrated evidence generation, nimble manufacturing practices, and clinically meaningful differentiation across treatment modalities.

Assessing how tariff-driven supply chain pressures are prompting diversification, nearshoring, and supply continuity strategies for acute lung injury therapeutics

The imposition of tariffs has heightened attention on supply chain design, manufacturing footprint decisions, and sourcing strategies for pharmaceutical inputs and finished formulations used in acute lung injury treatment. Companies that historically relied on geographically concentrated manufacturing are reassessing supplier diversification to mitigate tariff exposure and customs complexity. For many stakeholders, this has translated into a renewed emphasis on nearshoring options, dual-sourced active pharmaceutical ingredient (API) strategies, and contractual clauses that anticipate cross-border cost volatility.

Operational responses have included increased inventory buffers at hospital pharmacies coupled with closer collaboration between procurement teams and manufacturers to stabilize lead times and ensure continuity of care. Regulatory and quality oversight remain central to any sourcing shift, so firms pursuing alternative manufacturing arrangements prioritize established regulatory credentials and transparent audit trails. From a clinical perspective, continuity of access to established agents such as corticosteroids and neuromuscular blocking agents has been paramount, prompting contingency planning that aligns therapeutic protocols with available product formats and validated interchangeability strategies. Collectively, these adaptations underscore the importance of resilient supply networks and proactive stakeholder engagement in preserving treatment pathways amid tariff-driven disruptions.

In-depth segmentation insights linking drug classes, administration routes, care settings, and distribution channels to clinical application and operational execution

Segmentation analysis reveals differentiated demand drivers and operational considerations across drug classes, routes of administration, end-user profiles, distribution channels, patient age groups, and treatment settings. Across drug classes, corticosteroids command strategic attention with specific focus on agents such as dexamethasone, hydrocortisone, and methylprednisolone for their anti-inflammatory profiles, while neuromuscular blocking agents including cisatracurium, rocuronium, and vecuronium remain essential tools to facilitate lung-protective ventilation. Surfactant therapy, represented by agents like beractant and poractant alfa, continues to be critical in selected clinical scenarios where alveolar surface tension modulation offers clinical benefit, and inhaled vasodilators such as nitric oxide are deployed as adjuncts to improve oxygenation in refractory hypoxemia.

Route of administration drives logistical and clinical choices, with inhalation and intravenous options each presenting unique efficacy, onset, and safety trade-offs that inform protocol selection in the emergency department, general ward, or intensive care unit. End-user segmentation differentiates ambulatory care centers, hospitals, and research institutes by their clinical throughput, procedural capabilities, and research priorities, which in turn shapes expectations around product formats and support services. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacies; within hospital pharmacy operations, inpatient and outpatient pharmacy divisions have distinct inventory and dispensing workflows, while online channels include direct-to-patient and third-party fulfillment models that require careful cold-chain and regulatory compliance planning. Chain and independent retail pharmacies also play roles in outpatient transitions of care and patient access programs. Patient age group segmentation into adult, geriatric, and pediatric cohorts highlights dosing, safety, and formulation considerations that influence clinical decision-making and packaging design. Lastly, treatment setting segmentation across emergency departments, general wards, and intensive care units affects time-to-therapy imperatives, monitoring requirements, and interdisciplinary coordination needs, making alignment between therapeutic attributes and care environment essential for successful implementation.

Comparative regional analysis of care delivery models, regulatory dynamics, and supply chain considerations shaping acute lung injury treatment adoption globally

Regional dynamics shape clinical practice patterns, regulatory interactions, and commercial approaches for acute lung injury therapeutics across major global corridors. In the Americas, integrated hospital networks and a high degree of tertiary care capacity drive demand for protocols that emphasize rapid escalation to intensive care unit management, supported by advanced ventilatory technologies and established ICU pharmacy infrastructures. These characteristics favor therapies that integrate seamlessly with complex care pathways and where stakeholder engagement includes hospital formulary committees and critical care societies.

Europe, the Middle East & Africa encompasses a heterogeneous set of health systems, regulatory frameworks, and procurement models, which necessitates tailored market access strategies that account for national reimbursement mechanisms and region-specific clinical guidelines. Variability in critical care capacity and supply chain infrastructure in parts of this region can influence prioritization of stable supply channels and simplified administration profiles. Asia-Pacific features a mix of high-capacity urban tertiary centers and rapidly expanding regional care networks, with certain markets demonstrating accelerated adoption of digital health tools and tele-ICU models. In several parts of the region, manufacturing capacity and API production are significant factors that shape commercial negotiations and collaboration opportunities, and partnerships that address local clinical training and evidence generation often facilitate more rapid clinical integration. Across all regions, aligning regulatory strategy, evidence generation, and supply continuity plans with local clinical expectations remains central to successful implementation.

Strategic corporate priorities focusing on clinical evidence, manufacturing resilience, and partnership models to strengthen acute lung injury therapeutic delivery

Company-level dynamics are characterized by strategic investments in clinical development, manufacturing resilience, and collaborative partnerships that accelerate clinical adoption and strengthen supply continuity. Leading pharmaceutical developers are prioritizing evidence generation that demonstrates compatibility with contemporary ventilation and sedation protocols, while also investing in formulation innovations and packaging that facilitate rapid administration in acute care settings. Strategic alliances between manufacturers and contract development and manufacturing organizations are increasingly common to enhance scale flexibility and to support geographic diversification of production.

Commercially, companies are enhancing clinician engagement through targeted medical education, disease-state awareness initiatives, and real-world evidence programs that capture outcomes associated with varied treatment regimens. On the supply side, organizations are implementing advanced demand planning tools, serialized traceability, and quality-by-design practices to mitigate disruption risk and to satisfy heightened regulatory expectations. Additionally, some companies are expanding service offerings around patient support and hospital pharmacy integration to secure smoother transitions from acute care to outpatient follow-up. Collectively, these corporate strategies emphasize the integration of clinical relevance, operational robustness, and commercial agility to maintain continuity of care and to support evidence-informed decision-making across stakeholders.

Actionable strategic imperatives for manufacturers and healthcare leaders to strengthen clinical adoption, supply resilience, and integrated care pathways

Industry leaders should prioritize a set of pragmatic actions to enhance clinical impact, supply resilience, and commercial effectiveness for acute lung injury treatments. First, align clinical development and post-market evidence programs with contemporary critical care practice by designing studies that reflect modern ventilation strategies, common comorbidities, and pragmatic endpoints that matter to clinicians and hospital formulary committees. By doing so, organizations can reduce the evidence gap between regulatory approval and real-world clinical utility, supporting more rapid uptake and optimized care pathways.

Second, invest in diversified manufacturing and procurement strategies that balance cost efficiency with supply continuity, including dual sourcing of critical APIs, evaluation of nearshore production opportunities, and strengthened quality oversight across contract manufacturing partners. Third, deepen engagement with hospital pharmacy leaders, critical care clinicians, and procurement teams to co-design implementation protocols that address dosing convenience, storage constraints, and monitoring requirements across emergency departments, general wards, and intensive care units. Fourth, enhance digital and data infrastructure to capture real-world outcomes, support pharmacovigilance, and generate actionable insights for continuous improvement. Finally, develop flexible commercial models that consider hospital formulary dynamics and reimbursement environments, offering bundled service propositions and education programs that lower barriers to adoption while demonstrating clear operational benefits.

Robust mixed-methods research approach combining evidence synthesis, stakeholder interviews, and supply chain analysis to deliver clinically actionable insights

The research methodology underpinning this analysis combines systematic evidence synthesis, primary stakeholder engagement, and rigorous cross-validation of data to ensure reliability and relevance. The approach begins with comprehensive reviews of peer-reviewed clinical literature, regulatory approvals and labeling information, and publicly available clinical trial registries to establish a foundation of clinical evidence and safety profiles for the relevant therapeutic classes. This evidence base is then complemented by structured interviews with critical care clinicians, hospital pharmacy directors, and procurement leaders to surface practical insights about protocol preferences, operational constraints, and adoption barriers.

To capture distribution and operational dynamics, the methodology incorporates analysis of supply chain architectures, distribution channel practices, and regulatory compliance requirements, with particular attention to product formats and cold-chain considerations where relevant. Quality assurance steps include triangulation across multiple information sources, validation of key findings with subject matter experts, and sensitivity checks to ensure conclusions remain robust across divergent clinical and operational scenarios. Throughout, the research prioritizes transparency in data sources and methodological assumptions and emphasizes actionable interpretation to support decision-making by clinical, commercial, and operational stakeholders.

Synthesis of clinical, operational, and supply chain imperatives that must align to translate therapeutic advances into measurable improvements in patient outcomes

In conclusion, advancing the treatment of acute lung injury requires coordinated progress across clinical evidence generation, operational execution, and supply chain resilience. Therapeutic classes including corticosteroids, neuromuscular blocking agents, surfactants, and vasodilators each play defined roles within contemporary treatment paradigms, and their effective deployment depends on alignment with administration routes, care settings, and distribution models that meet the realities of acute care delivery. Addressing tariff-induced supply vulnerabilities and regional regulatory heterogeneity further necessitates proactive sourcing strategies and localized engagement to ensure uninterrupted patient access.

Moving forward, stakeholders who invest in pragmatic evidence generation, clinician-centered implementation design, and manufacturing flexibility will be best positioned to translate scientific advances into meaningful improvements in patient outcomes. Coordination across hospital systems, suppliers, and regulatory bodies remains essential to harmonize expectations and to streamline pathways from therapy availability to routine clinical use. Ultimately, the integration of rigorous clinical data, resilient operations, and collaborative stakeholder engagement will determine the trajectory of therapeutic impact for patients experiencing acute lung injury.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging biomarker-guided personalized therapies for acute lung injury management
  • 5.2. Adoption of point-of-care ultrasound protocols to optimize fluid management in ALI patients
  • 5.3. Clinical trial advancements in mesenchymal stem cell therapies targeting acute respiratory distress syndrome
  • 5.4. Integration of AI-driven predictive analytics for early detection of acute lung injury risk
  • 5.5. Regulatory approval pathways expediting novel inhaled anti-inflammatory agents for ALI
  • 5.6. Implementation of tele-ICU platforms to support ventilator weaning strategies in acute lung injury
  • 5.7. Development of extracorporeal carbon dioxide removal systems improving outcomes in severe ALI
  • 5.8. Expansion of wearable biosensors for continuous respiratory monitoring in high-risk patients
  • 5.9. Real-world evidence studies evaluating high-flow nasal cannula efficacy in moderate to severe ALI
  • 5.10. Pharmaceutical collaborations focusing on lipid nanoparticle drug delivery for pulmonary inflammation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Lung Injury Treatment Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Dexamethasone
    • 8.1.2. Hydrocortisone
    • 8.1.3. Methylprednisolone
  • 8.2. Neuromuscular Blocking Agents
    • 8.2.1. Cisatracurium
    • 8.2.2. Rocuronium
    • 8.2.3. Vecuronium
  • 8.3. Surfactants
    • 8.3.1. Beractant
    • 8.3.2. Poractant Alfa
  • 8.4. Vasodilators
    • 8.4.1. Nitric Oxide

9. Acute Lung Injury Treatment Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Intravenous

10. Acute Lung Injury Treatment Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Acute Lung Injury Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Inpatient Pharmacies
    • 11.1.2. Outpatient Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Direct To Patient
    • 11.2.2. Third Party Fulfillment
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Acute Lung Injury Treatment Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Acute Lung Injury Treatment Market, by Treatment Setting

  • 13.1. Emergency Department
  • 13.2. General Ward
  • 13.3. Intensive Care Unit

14. Acute Lung Injury Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Acute Lung Injury Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Acute Lung Injury Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Medtronic plc
    • 17.3.2. Koninklijke Philips N.V.
    • 17.3.3. General Electric Company
    • 17.3.4. Dragerwerk AG & Co. KGaA
    • 17.3.5. Fisher & Paykel Healthcare Corporation Limited
    • 17.3.6. Hamilton Medical AG
    • 17.3.7. Smiths Group plc
    • 17.3.8. Getinge AB
    • 17.3.9. Vyaire Medical, Inc.
    • 17.3.10. Nihon Kohden Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE LUNG INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA ACUTE LUNG INJURY